| Date Completed: |  |
|-----------------|--|
|                 |  |

## Survivorship Care Plan for Immuno-Oncology Therapies

|   | TREATMEN  | ΓSUMMARY                 |                 |  |  |  |
|---|---|--------------------------|-----------------|--|--|--|
| Name of Patient:  |   |                          |                 |  |  |  |
| Oncologist:   |   | Contact Info:            |                 |  |  |  |
|   |   | Contact inio.            |                 |  |  |  |
| DIAGNOSIS   |   |                          |                 |  |  |  |
| Cancer Type/Location/Pathology:<br>Ex. Poorly differentiated carcinoma                                | of the left breast; Ki-67 of 30%  | ó                        | Diagnosis Date: |  |  |  |
|   |   |                          | Stage:          |  |  |  |
|   |   |                          |                 |  |  |  |
|   | TREATMENT WITH  |                          |                 |  |  |  |
| Names of Agent(s) Used  | Completion Date:<br>(n/a, if ongoing)   | Side Effects Experienced |                 |  |  |  |
| •   |   |                          |                 |  |  |  |
| •   |   |                          |                 |  |  |  |
| 0   |   |                          |                 |  |  |  |
| Clinical Trial?   | Initiation and Completion Dates: (If treatment is ongoing, choose "Current".) |                          |                 |  |  |  |
| ☐ Yes ☐ No  | Initiation:   | _ Completion: Current    |                 |  |  |  |
| Clinical Trial Information: Name/# of trial, expected f/u, study-specific contact names/numbers, etc. |   |                          |                 |  |  |  |
| Persistent symptoms or treatment side effects   |   |                          |                 |  |  |  |
| ☐ Yes ☐ No If yes, explain below:   |   |                          |                 |  |  |  |
|   |   |                          |                 |  |  |  |
|   |   |                          |                 |  |  |  |
|   |   |                          |                 |  |  |  |
|   |   |                          |                 |  |  |  |

| FOLLOW-UP CARE PLAN   |   |   |                |  |  |  |  |
|---|---|---|----------------|--|--|--|--|
| LATE/LONG-TERM EFFECTS OF SYSTEMIC IO THERAPY   |   |   |                |  |  |  |  |
| Common Side Effects:  Gastrointestinal: Diarrhea, colitis, acute pancreatitis Pneumonitis: Inflammation in the lungs Dermatologic: Rashes and itchiness |   | ☐ Endocrine: Diabetes, thyroid ☐ Musculoskeletal: Arthralgia, arthritis ☐ Cardiovascular: Pericarditis, myocarditis, arrhythmia ☐ Kidney infections |                |  |  |  |  |
| Need for Ongoing (Maintenance) Treatment for Cancer:  |   |   |                |  |  |  |  |
| Additional Treatment Name   | Planned Duration  | Possible Side Effe  | ects           |  |  |  |  |
|   |   |   |                |  |  |  |  |
|   |   |   |                |  |  |  |  |
|   |   |   |                |  |  |  |  |
|   |   |   |                |  |  |  |  |
| GENERAL PHYSICAL AND PSYCHOSOCIAL SUPPORT ASSESSMENT FOR IO SURVIVORS   |   |   |                |  |  |  |  |
| Area  | Focus   |   | Recommendation |  |  |  |  |
| Cancer-Specific Follow Up   | ☐ Imaging ☐ Other:  |   |                |  |  |  |  |
| Physical Well-Being   | ☐ Diet ☐ Exercise ☐ Health screenings ☐ Other:  |   |                |  |  |  |  |
| Sexual Health   | ☐ Fertility ☐ Sexual side effects ☐ Intimacy/Relationship ☐ Other:  |   |                |  |  |  |  |
| Psychosocial Well-Being   | ☐ Common: Anxiety and d☐ Changing sense of self☐ Fatigue and burn out☐ Other:   | epression   |                |  |  |  |  |
| Financial Assessment  | <ul> <li>☐ Hardship related to cost of medical treatments</li> <li>☐ Hardship related to non-medical costs</li> <li>☐ Other:</li> </ul> |   |                |  |  |  |  |
| Palliative Care   | Pain management Other:  |   |                |  |  |  |  |
| Other   |   |   |                |  |  |  |  |
| Other   |   |   |                |  |  |  |  |

The ACCC Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for cancer care teams across all healthcare settings.

Access survivorship resources for patients on cancer immunotherapies at accc-cancer.org/home/learn/immunotherapy/survivorship.

